Category: 2012Syndicate content

Sales are flat, profits plunge in the 2nd quarter for Symmetry Medical

August 5, 2013 by Brad Perriello

Sales were flat and profits slid 28% for Symmetry Medical during the 2nd quarter as it lowers its sales and earnings outlook for the rest of the year.

Sales are flat, profits plunge in the 2nd quarter for Symmetry Medical

Symmetry Medical (NYSE:SMA) saw its 2nd-quarter profits plunge more than 28% on flat sales and lowered its outlook for the balance of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet swings to Q4 black, pares fiscal 2013 losses

July 11, 2013 by Brad Perriello

Biomet swings to 4th-quarter profits and pares its losses for fiscal 2013, saying joint reconstruction sales were off 1% for the quarter.

Biomet swings to Q4 black, pares fiscal 2013 losses

Biomet said it posted black ink during the 4th quarter and cut its losses for fiscal 2013, reporting a 1.0 % decline in large joint reconstruction sales.

The privately held medical device company, which is said to be considering an IPO or sale, is closely watched as a bellwether for the orthopedic market, which has been bedeviled in recent years by falling procedure volumes for hip and knee replacements.

EDAP’s losses widen, sales increase in 2012

June 3, 2013 by Sony Salzman

EDAP posts an increase in sales and deepening losses in its fiscal 2012 report.

Edap TMS

EDAP (NSDQ:EDAP) posted a slight bump in sales but a dramatic increase in losses for the fiscal year of 2012

The French device maker posted year-end losses of $9.7 million, or 55¢ per diluted share, on sales of $33.7 million. That compares with 2011 losses of $1.3 million, or 10¢ per diluted share, on sales of $31.2 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA accepts Edap's Ablatherm PMA application

April 10, 2013 by Sony Salzman

The FDA accepts Edap SA's pre-market approval application for its Ablatherm prostate cancer treatment, as 2012 losses soar for the French medical device company.

Edap TMS

Edap (NSDQ:EDAP) said the FDA accepted its pre-market approval application for its Ablatherm ultrasound prostate cancer treatment, backed by data from its Enlight investigational device exemption study.

The Vaulx-en-Velin, France-based medical device company also reported that its losses increased by a whopping 646% during the 2012, on an 8% sales increase.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA approves 1st Type 2 diabetes drug | Wall Street Beat

April 1, 2013 by Brad Perriello

The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.

MassDevice.com Wall Street Beat

The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Sanuwave slashes workforce by 65%, but pares losses by more than a third

April 1, 2013 by Sony Salzman

Sanuwave cuts 18 of 28 employees, helping to pare its 2012 losses by 38%.

Sanuwave logo

Sanuwave Health (OTC:SNWV) laid off more than ⅓ of its workforce in its quest to pare its 2012 losses, according to a regulatory filing, shrinking from 28 employees to 10.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Kips Bay rises on FDA trial approval, despite losses in sales and revenue

March 29, 2013 by Arezu Sarvestani

Kips Bay reports widening losses and shrinking sales for its 4th quarter, but the FDA's decision to allow full enrollment in the U.S. arm of the company's feasibility trial is an important turnaround for the device maker.

Kips Bay logo

Medical device maker Kips Bay Medical (NSDQ:KIPS) saw widening losses and sinking sales during its most recent quarter, but the company marked an important win with FDA approval to complete full enrollment in the U.S. arm of a feasibility study.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp